New real-world data from the 1INSPIRE study shows that frontline niraparib (Zejula) maintenance is well-tolerated in patients ...
Mirvetuximab soravtansine shows 16.4-month OS in ovarian cancer, though poor ECOG status and toxicity significantly impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results